礼来口服减重药再添头对头达格列净数据,市值逼近8000亿美元

第一财经
Oct 16

当地时间10月15日,礼来公司公布两项关于口服减重药Orforglipron的后期临床数据,显示出对糖尿病患者的血糖控制效果。礼来和诺和诺德等制药商正在寻求扩大GLP-1类减重药物市场的领先地位。  最新发布的数据中,一项重磅的研究是将礼来Orforglipron与阿斯利康畅销的降糖药达格列净进行头对头的比较,结果显示,在二甲双胍血糖控制不佳的2型糖尿病成人患者中,Orforglipron对血糖...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10